Vacinex is a tiny company, $74 million market cap and approximately 29 million shares outstanding. They have beat street earnings expectations the past 2 quarters and they are working with Merck and the "keytruda" drug for an Alzheimer's "proof of concept" study. If the drug performs like it should, well, than you can guess where the price goes. 15% held...
Vaccinex, inc. has been in my portfolio now since March. Strong technical charting is how I came across the stock itself not fundamentals. I bought in around $1.20, but hopefully my charting shows you how low the dip is we are currently in and the obvious downwards regression channel trend. Insiders have been buying away as well which isn't a bad sign for the...
Hopefully you find the chart helpful in terms of Supports & Resistance etc. we refrain from adding commentary on the chart as that is reserved for our members and we are very conscious of not giving financial or trading advice. Thank you for taking time to consult our chart and we would really appreciate a like, follow or comment.
Technical Analysis, The best option is to hold as technical analysis suggests to go short while fundamental to go long. Fundamental Analysis Vaccinex stock rocketed up more than 200% Friday, propelled by two collaboration deals centered on using the biotech company's antibody discovery platform NASDAQ:VCNX
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform Partnerships will use Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery www.globenewswire.com
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the...
Breakout and close above trend line